Alba Therapeutics Announces Phase IIb Clinical Trial For Oral AT-1001 For The Treatment Of Celiac Disease

Alba Therapeutics Corporation today announced that it has dosed its first patient in a six-week Phase IIb trial with oral AT-1001, an inhibitor of gastrointestinal barrier dysfunction, for the maintenance of remission in patients with Celiac Disease (CD). [click link for full article]

More: continued here

Filed under: GastroIntestinal / Gastroentorology on September 20th, 2007